Zoetis Inc.

▲ Bull Case

• ◆Librela reaches $2B+ revenue by FY2029 — the most underpenetrated product in vet pharma. An estimated 40M dogs in the US have osteoarthritis; Librela is a monthly injection at ~$100-130/dose. Current penetration: <5% of eligible dogs in the US, <2% globally. Even reaching 10-15% US penetration (with global following) = $1.5-2B from a product that costs essentially zero to manufacture at marginal unit. Pipeline: feline Librela (different molecule), avian pain mAbs in development. The pain franchise is 3-5x larger than current revenue at full penetration.
• ◆Renal mAb (FKD-1 / anti-FGF23) launches FY2027 — first disease-modifying therapy for cat CKD. Feline chronic kidney disease (CKD) affects ~30-40% of cats over age 10. No disease-modifying treatment exists; current care is palliative (IV fluids, diet modification). A monoclonal antibody that slows CKD progression would capture the largest unmet need in companion animal medicine. Phase 3 data (positive Phase 2): if FDA-approved, ZTS could reach $500M-1B renal revenue within 3 years of launch. This is not in consensus estimates.
• ◆Multiple re-rates from 14x → 20x+ as growth re-accelerates. Once FY2027 revenue shows 7-9% organic growth (Pain mAb + renal mAb + derm stabilization), the market re-rates from 'deceleration multiple' to 'growth compounder multiple.' At 20x FY2028E EPS $8.75 = $175; at 22x = $193.

▼ Bear Case

• ◆Zenrelia + generic parasiticides = double compression by FY2027-2028. Elanco's Zenrelia (IL-31 inhibitor for atopic dermatitis) has a differentiated mechanism (approved for dogs; cats pending) and Elanco is marketing aggressively. If Zenrelia captures 30%+ of new derm scripts AND Simparica Trio generics enter in FY2027 (patent expiry), ZTS faces $500-700M in combined revenue headwinds. Margin deleverages; EPS flatlines. FY2028 EPS $6.50 at 14x = $91 (-21% from $115).
• ◆Librela safety escalation (black-box warning). If FDA issues a black-box warning — the most severe US drug warning, requiring prominent label disclosure — vet prescribers would dramatically reduce Librela use. Major veterinary academic centers (Cornell, Tufts, UC Davis) have been cautious about Librela; a formal safety escalation could cut Pain mAb revenue in half within 2 quarters. This is a binary event: $115 → $70-80 immediately if escalation occurs.
• ◆Permanent de-rating to 15x P/E (the 'new reality' scenario). The market has been slowly re-rating ZTS from growth multiple (28-35x) to mature pharma multiple (15-20x) as growth decelerated. If the market decides ZTS is fundamentally a 5-6% grower (not a 10%+ compounder), the appropriate P/E is 15-17x rather than 20-25x. At 15x FY2028E $8.75 = $131 — not deep downside but meaningful multiple compression vs. bull case.

“Is Zoetis's growth deceleration cyclical (solvable via Pain mAb + pipeline) or structural (the best years are behind us)? Consensus (61% Buy, 31% Hold, 8% Sell; PT $130-155) is constructive but has cut estimates 3 times in 18 months. The bull camp: 2.3% FY2025 growth is a trough; Librela is a multi-billion opportunity; renal mAb is a pipeline nobody has properly modeled; ZTS at 14x FY2027E is historically cheap for the #1 animal health franchise. The bear camp: Pain mAb safety will remain an overhang; Elanco is well-funded and Zenrelia is better positioned; China is gone permanently; ZTS is a $6-7/share earnings company forever. Our Step_14 analysis: at $115 / 14.4x FY2027E adj. EPS, the market is pricing the bear case with zero credit for renal mAb pipeline or Pain mAb normalization. The base case ($158) and bull case ($220) are both above current price. The bear case ($91) is real but requires two simultaneous product headwinds materializing — each independent with ~20-30% probability.”

• ◆Q2 2026 earnings (Aug 2026): Pain mAb revenue trend + FDA safety update — VERY HIGH impact
• ◆Renal mAb Phase 3 data read-out (FY2026): first disease-modifying cat CKD therapy — VERY HIGH impact
• ◆FDA no further action on Librela (12+ months silence): safety normalization — HIGH impact
• ◆Zenrelia market share data (quarterly via Elanco): derm competitive pressure tracking — MEDIUM-HIGH impact
• ◆FY2026 adj. EPS beat guidance (Nov 2026): above $7.10 signals momentum — HIGH impact

• ◆Librela safety escalation to black-box warning (8-10% probability, VERY HIGH severity): binary event → $45-70 downside
• ◆Zenrelia >30% derm market share (20% probability, HIGH severity): Elanco competitive gain; $400M+ headwind by FY2027
• ◆Generic parasiticides entering FY2027 (30% probability, MEDIUM severity): Simparica Trio patent expiry; IP defense ongoing
• ◆Renal mAb Phase 3 failure (20% probability, MEDIUM severity): removes bull optionality; base case intact
• ◆China permanent structural decline (25% probability, LOW-MEDIUM severity): already declining; $200M floor well-supported